Immune cell therapy takes on stubborn muscle weakness
NCT ID NCT07243366
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new treatment for people with refractory myasthenia gravis, a condition causing severe muscle weakness. The treatment uses donor immune cells (CAR-NK cells) engineered to target and calm the immune system's attack on muscles. Fifteen participants will receive infusions every two weeks for 24 weeks, with researchers monitoring safety and any changes in daily living and muscle strength.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD19-CAR-NK cells (immune cells engineered to target CD19)
What this could lead to
If it works, this could point toward a new treatment option for people with hard-to-control myasthenia gravis.
What could go wrong
This is a very early, small trial (15 people) testing safety first. The treatment may not improve symptoms, and side effects from the immune cells are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••